Fig. 2

Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma correlates with increased numbers of infiltrating CD163⁺ cells. (a) Representative data of immunohistochemistry staining of IL-34 (left) or melanoma antigens (right) was compared between primary or Nivolumab-resistant metastatic melanoma tissues. Bar graph on the right shows mean fluorescence intensity of IL-34 or melanoma antigens staining in tumor areas. (b) Immunohistochemistry staining of CD163 was compared between primary or Nivolumab-resistant metastatic melanoma tissues. Bar graph on the right shows frequencies of CD163⁺ cells in the indicated samples. Data is shown as mean ± SEM. *P < 0.05